Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Shares Issued (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Shares Issued for 6 consecutive years, with -$476000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 935.09% year-over-year to -$476000.0, compared with a TTM value of $533000.0 through Sep 2025, down 99.5%, and an annual FY2024 reading of $428000.0, down 99.6% over the prior year.
  • Shares Issued was -$476000.0 for Q4 2025 at Treace Medical Concepts, down from $241000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $107.2 million in Q2 2023 and bottomed at -$105.8 million in Q3 2023.
  • Average Shares Issued over 5 years is $5.9 million, with a median of $194000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 6873.0% in 2023, while the deepest fall reached 6785.88% in 2023.
  • Year by year, Shares Issued stood at $1.0 million in 2021, then skyrocketed by 113.16% to $2.2 million in 2022, then soared by 4739.32% to $105.8 million in 2023, then crashed by 99.95% to $57000.0 in 2024, then crashed by 935.09% to -$476000.0 in 2025.
  • Business Quant data shows Shares Issued for TMCI at -$476000.0 in Q4 2025, $241000.0 in Q3 2025, and $116000.0 in Q2 2025.